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ABSTRACT
Objectives Cerebral palsy (CP) remains the world’s 
most common childhood physical disability with total 
annual costs of care and lost well-being of $A3.87b. 
The PREDICT-CP (NHMRC 1077257 Partnership Project: 
Comprehensive surveillance to PREDICT outcomes for 
school age children with CP) study will investigate the 
influence of brain structure, body composition, dietary 
intake, oropharyngeal function, habitual physical activity, 
musculoskeletal development (hip status, bone health) 
and muscle performance on motor attainment, cognition, 
executive function, communication, participation, quality 
of life and related health resource use costs. The PREDICT-
CP cohort provides further follow-up at 8–12 years of two 
overlapping preschool-age cohorts examined from 1.5 to 
5 years (NHMRC 465128 motor and brain development; 
NHMRC 569605 growth, nutrition and physical activity).
Methods and analyses This population-based cohort 
study undertakes state-wide surveillance of 245 children 
with CP born in Queensland (birth years 2006–2009). 
Children will be classified for Gross Motor Function 
Classification System; Manual Ability Classification 
System, Communication Function Classification System 
and Eating and Drinking Ability Classification System. 
Outcomes include gross motor function, musculoskeletal 
development (hip displacement, spasticity, muscle 
contracture), upper limb function, communication 
difficulties, oropharyngeal dysphagia, dietary intake and 
body composition, participation, parent-reported and 
child-reported quality of life and medical and allied health 
resource use. These detailed phenotypical data will be 
compared with brain macrostructure and microstructure 
using 3 Tesla MRI (3T MRI). Relationships between brain 
lesion severity and outcomes will be analysed using 
multilevel mixed-effects models.
Ethics and dissemination The PREDICT-CP protocol is 
a prospectively registered and ethically accepted study 
protocol. The study combines data at 1.5–5 then 8–12 
years of direct clinical assessment to enable prediction 
of outcomes and healthcare needs essential for tailoring 
interventions (eg, rehabilitation, orthopaedic surgery and 
nutritional supplements) and the projected healthcare 
utilisation.
Trial registration number ACTRN: 12616001488493
Background
Cerebral palsy (CP) is a disorder of move-
ment and posture secondary to an insult to 
the developing brain.1 The insult is static and 
permanent and may be the consequence of 
different factors, including both genetic and 
environmental causes. Although the insult is 
static, the consequent symptoms are variable 
and may change over time.2 The disability 
increases with age and ageing occurs earlier.3 
Children may have a range of comorbidities,4 
which are likely to impact outcomes and 
costs of care.5 Based on CP registers, a recent 
Strengths and limitations of this study:
 ► The PREDICT-CP  prospective cohort study 
provides comprehensive phenotypical data on a 
representative cohort of children with cerebral palsy.
 ► The longitudinal follow-up of this cohort (at 2–5 
years and now cross-sectional at 8–12 years) 
will enable development of prediction models of 
outcome.
 ► Brain structure (macrostructure and microstructure 
at 3.0 T) will be compared with  comprehensive 
motor, cognitive and communication outcomes at 
school age.
 ► A limitation is that only brain macrostructure at 1.5 T 
has been captured from early clinical brain MRI 
scans as part of clinical practice.
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systematic review identified that in children diagnosed 
with CP at 5 years: 3 in 4 were in pain; 1 in 2 had an intel-
lectual disability; 1 in 3 could not walk; 1 in 3 had hip 
displacement; 1 in 4 could not talk; 1 in 4 had epilepsy; 1 
in 4 had a behaviour disorder; 1 in 4 had bladder control 
problems; 1 in 5 had a sleep disorder; 1 in 5 dribbled; 1 
in 10 were blind; 1 in 15 were tube fed and 1 in 25 were 
deaf.6 It is known that peak motor attainment in CP is 
reached at 8–9 years and tends to plateau before a decline 
in adolescence.3 Secondary musculoskeletal disorders 
involving muscle, tendons, bones and joints are common 
as a result of spasticity, muscle weakness and immobility. 
CP has substantial lifelong effects on daily function, 
societal participation and quality of life (QoL) for chil-
dren and their families. There is a paucity of data on 
the relationship between physical outcomes and school 
attainment.7 Better prediction of outcomes is important 
for families and healthcare providers.8
In Australia, CP remains the most common physical 
disability in children with ≈ 700 infants born each year 
that will be later diagnosed with CP.9 The overall costs to 
society of persons with CP was $A1.47b per year (0.14% 
of GDP), with an average annual cost of $A43 431 per 
individual.10 When taking into account the value of lost 
well-being (disability and premature death), the total 
costs were $A3.87b per year or $A115 000 per person. 
CP has a lifetime impact at a total cost of over $A2M 
per person.10 More recently, in a preschool-aged cohort 
(CP-Child, National Health and Medical Research 
Council NHMRC 465128), we have determined a strong 
relationship between severity of Gross Motor Function 
Classification System (GMFCS) levels I–V and a stepwise 
increase in incremental costs of care.5
The ability to better predict outcomes has the poten-
tial to guide intervention to reduce adverse outcomes 
(hip dislocation, poor growth, undernutrition or 
overnutrition, respiratory health complications from 
oropharyngeal dysphagia (OPD), pain, reduced participa-
tion in the community and under attainment at school). 
Development of prediction models based on early brain 
structure and function can inform health and social 
care provision (eg, via the National Disability Insurance 
Scheme (NDIS)) and provide best practice comprehen-
sive surveillance to allow implementation of timely and 
effective interventions to achieve optimal outcomes.
Understanding the relationship between specific brain 
MRI appearance and outcome measures such as motor 
function is critically important.11 Such data may prove 
invaluable in providing accurate prognostic counselling 
at the time of diagnosis, as well as potentially guiding the 
most appropriate treatments tailored to each individual’s 
pattern of CP and type and severity of the brain lesion 
on imaging.12 A focus of the majority of epidemiological 
research is the prevention of CP, which requires clinical 
outcomes to be correlated with the presumed timing and 
aetiology of lesions in the developing brain.11 Patholog-
ical insults in the developing brain cause abnormalities 
or lesions, which may be detected by brain MRI, and 
the patterns of these lesions depend on the stage and/
or presumed timing of the injury during brain devel-
opment.13 Using this principle, a qualitative system of 
classification is established, whereby lesions can be iden-
tified as brain maldevelopments (occurring in the first 
and second trimesters),11 periventricular white matter 
lesions (occurring early in the third trimester and in 
preterm infants) or grey matter lesions (occurring late 
in the third trimester and at term).11 A systematic review 
found studies with enough MRI data for subjects to be 
classified into these presumed lesion timing groups, 
and in the majority of studies this lesion timing classifi-
cation was able to be linked to at least one measure of 
motor outcome.11 There are limited data on brain lesion 
severity, brain microstructure and quantitative compre-
hensive outcomes.11
In the Australian CP-child study, entire birth years of 
Victorian and Queensland born children with CP across 
the full spectrum of gross motor abilities were prospec-
tively followed to determine the relationship between 
the rate and limit of motor development (gross and fine 
motor function) as related to the nature of the brain 
lesion.12 14 Representative population-based data have 
been reported on i) early development and prediction of 
hip outcomes,15 ii) the relationship between brain struc-
ture and motor development12 and iii) social function16 
and communication17 with cost and health resource use 
data across the spectrum of functional severity.5 The 
cross-sectional domains of school readiness (mobility, 
self-care, social function, communication) were reported 
at school entry.16 18
In CP, there is a likely relationship between the severity 
of the early brain injury on structural MRI (nature, extent, 
presumed timing), early motor status at 3 years and later 
outcomes at 8–12 years (motor attainment, musculoskel-
etal performance, hip displacement). In Sweden, Norway 
and Scotland, a population-wide surveillance programme 
(CP-UP) has been implemented for up to 10 years.19 
Since implementation in Southern Sweden, no child with 
CP has had a dislocated hip,19 musculoskeletal contrac-
tures have been reduced20 and nutrition and bone health 
are monitored.21 22 National hip surveillance best prac-
tice guidelines have been developed and implemented 
in Australia,23 and in Queensland population-wide hip 
surveillance has been implemented.24
The PREDICT-CP study will undertake further compre-
hensive follow-up of four birth years of children with 
CP born in Queensland to capture longitudinal data on 
growth and physical outcomes (motor capacity, muscle 
and bone health, physical activity, feeding and oropha-
ryngeal function, nutrition), cognition (executive 
function, educational attainment, communication) and 
participation, QoL, pain and these are related to costs 
of healthcare utilisation. The quantitative evaluation 
of early brain structure on MRI and functional status 
around 2 years will be compared with these comprehen-
sive outcomes at 8–12 years to build prediction models 
of CP. Development and implementation of prediction 
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models of outcomes are essential for tailoring interven-
tions (rehabilitation, medical management, orthopaedic 
surgery, nutritional supplements) and in understanding 
the likely costs of healthcare.
Growth, nutrition and physical activity are important 
determinants of health outcomes in children with CP. 
Knowledge of levels and patterns of habitual physical activity 
(HPA) for children with CP are important as they have 
increased risk of inactivity (sedentary behaviour) related 
illness.9 25 In addition, poor nutrition and growth may 
have a secondary impact on body composition, bone 
health and brain maturation, as well as participation and 
health-related quality of life (HRQoL) in later childhood. 
In our overlapping CP-child study of growth, nutrition 
and physical activity (NHMRC 569605),26 we have deter-
mined at preschool-age the i) energy requirements, body 
composition, dietary intake,27–29 ii) validation of HPA 
cut-points,30 iii) validation of a modified 3-day weighed 
food record for the assessment of energy intake29 and iv) 
OPD across the spectrum of functional severity.31 32
Our early data on nutritional status29 used gold stan-
dard measures (doubly labelled water) to determine the 
energy requirements of preschool-aged children with CP 
compared with age-matched children with typical devel-
opment (TD).28 Children who were GMFCS III–V had 
energy requirements 18% lower than ambulant children 
and 31% lower than children with TD,28 with no differ-
ences between ambulant children with CP and children 
with TD. In addition, energy intake was related to fat-free 
mass (FFM) index in both children with CP and children 
with TD.29 Associations were identified between OPD, 
energy intake and nutritional status after GMFCS level 
was taken into account. At preschool age, OPD was orig-
inally reported in 85% of our cohort, with a significantly 
greater proportion of OPD with each increase in GMFCS 
level.31 Following further testing of OPD psychometrics, 
with the inclusion of a typically developing reference 
sample, modified cut-points were developed resulting in 
a revised estimate of 56%.33 Children on full oral intakes 
that required modification (texture or additional energy 
and protein) were most at risk of poor growth and nutri-
tional status.31
HPA accelerometer cut-points have been determined 
for sedentary and active behaviour in toddlers with CP,34 
demonstrating that HPA levels are highly variable within 
GMFCS levels particularly GMFCS I–II.35 The musculo-
skeletal development of children with CP has focused on 
how spasticity interferes with normal muscle growth, and 
contributes to reduced joint range of motion, increased 
joint stiffness and muscle weakness.36 These factors lead to 
fixed contractures of the muscle-tendon unit and skeletal 
deformity that may require orthopaedic surgery.37 These 
secondary alterations progress with age38 and contribute 
to reduced gait speed, increased joint pain and falling, 
culminating in reduced HPA.39 Muscle adaptations begin 
early37 and compared with children with TD vary in the 
following ways: i) muscle volume is reduced36 40 41; ii) 
muscle fascicles are stiffer when passively stretched40; iii) 
muscle fascicles cannot stretch to lengths more favour-
able for force production42 and iv) the Achilles tendon 
is longer.42 43 This effectively means that the ability of 
muscle to generate force is reduced in children with CP. 
In ambulant children (GMFCS I–III), the calf muscle 
(gastrocnemius/soleus) has a major role in forward 
propulsion during walking/running44 and structural/
functional adaptations are a cause of gait limitations.45 
Characteristics of muscle structural/functional adapta-
tions also vary according to unilateral/bilateral motor 
distribution.46 Lower limb treatments (casting, intramus-
cular Botulinum toxin A injections) aim to manage these 
adaptations in the preschool years; however, multilevel 
orthopaedic surgery is often required at functional attain-
ment (8–11 years) according to a child’s gait profile.47 48 A 
gait profile of ambulant children (GMFCS I–III) combined 
with muscle properties would provide important infor-
mation for surgical decision making and prediction of 
functional outcome. Examination and surveillance of 
the relationship between muscle structure/function and 
gait profile to functional capacity/performance, physical 
activity, bone health, nutritional status and healthcare 
costs would provide vital information for structuring 
management plans into later childhood.
The broad aim of the CP-child studies is to implement 
population-based comprehensive surveillance of chil-
dren with CP from early diagnosis (at 1.5–3 years) based 
on brain structure and function (early gross and fine 
motor, growth, nutrition, HPA, musculoskeletal devel-
opment) to predict comprehensive outcomes at school 
age (8–12 years), a time of definitive motor maturation, 
walking ability, need for orthopaedic intervention and 
educational attainment. In this extended follow-up of 
two previous overlapping prospective population-based 
CP cohorts (followed from 18 to 24 months corrected 
age to 5 years) across the full spectrum of functional 
severity (NHMRC 46512814; NHMRC 569605),26 we will 
re-examine the relationship to severity of brain struc-
ture at 8–12 years on diffusion MRI (dMRI in a 3.0 T 
MRI scanner). At 8–12 years, healthcare utilisation is 
likely to be different to preschool-age so that associations 
between health resource use and a beneficial health/
social outcome can be re-evaluated. The PREDICT-CP 
child study (NHMRC 1077257) is prospectively registered 
at ACTRN: 12616001488493.
aims and hypoTheses
The PREDICT-CP study will undertake comprehensive 
state-wide surveillance (in Queensland) of four birth 
years of a representative population-based cohort of 
children with CP. The relationship between brain struc-
ture on growth and physical outcomes (motor capacity, 
muscle and bone health, physical activity, oropharyn-
geal function, nutrition), cognition (executive function, 
educational attainment, communication) and partici-
pation (HPA, QoL, pain and sleep), will be related to 
educational attainment and health resource use costs.
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hypotheses
1. The location, extent of the brain lesion(s) on semi-
quantitative MRI (by 2 years) and early motor 
capacity and performance (1.5–3 years) will predict 
severity of motor capacity Gross Motor Function 
Measure (GMFM-66) and performance (6 min walk 
test  (6MWT)), Paediatric Evaluation of Disability 
Inventory Computer Adaptive Test (PEDI-CAT) at 
8–12 years.
2. The rate and limit of gross motor and fine motor 
development (GMFM-66, Assisting Hand Assessment 
(AHA), Both Hands Assessment (BoHA)), at 
8–12 years will be influenced by the severity of 
musculoskeletal deformity (ie, slower development 
will correlate with increased spasticity/contracture, 
poor muscle function, marked hip displacement, 
pain, reduced sleep, reduced manual ability).
3. Cognition, executive function, communication and 
educational attainment will be related to brain lesion 
severity (location, extent of the brain lesions) on 
semi-quantitative MRI but not gross and fine motor 
capacity (GMFCS, Manual Ability Classification 
System (MACS)) at 8–12 years.
4. Nutritional status (under/overweight), OPD, body 
composition (FFM and fat mass (FM) via dual energy 
X-ray absorptiometry (DXA)), HPA, growth velocity 
and bone health will be related to the level of GMFCS 
attainment and will predict: i) higher healthcare 
utilisation and direct medical costs; ii) lower levels of 
participation in school, leisure and community and 
iii) poorer HRQoL.
study significance
For children with CP, this unique project will:
1. Quantify the impact of functional severity on medical 
resource use to inform service provision planning 
at school age (a period of intensive medical and 
orthopaedic treatments). From earlier sampling 
of these cohorts (NHMRC 465128/569605), we 
have detailed information on the content, dose and 
compliance, adverse events, medical, surgical and 
allied health resource use (interventions, medications, 
equipment) and consequences of outcome (from the 
age of 1.5 to 5 years). By study completion, we will 
have lifetime data on all interventions from age 1.5 
to 5 years and 8–12 years, with regular assessments of 
their functional status/outcomes allowing predictive 
modelling of outcomes for children with CP.
2. Provide school-age follow-up of this comprehensively 
studied cohort enabling: i) prediction of outcome 
(brain structure and multiple outcomes); 
ii) prognostication on functional, cognitive, 
communication for school attainment; iii) risk factors 
for musculoskeletal problems (ie, hip, spine deformity 
and need for surgery) and iv) health outcomes due 
to sedentary behaviour, body composition, dietary 
intake and OPD.
3. Highlight the contribution of poor dietary intake, low 
levels of HPA and reduced bone health on growth, 
body composition and fracture risk, taking into 
account the severity of disability.
4. Define the relationship between HPA levels, motor 
capacity and muscle performance to predict eventual 
functional attainment and community performance.
As CP remains the most common childhood physical 
disability with high lifetime costs, models to predict 
outcomes and costs of care will inform health provision, 
social care and tailor data for national funding schemes 
such as the Australian NDIS.
meThods
All children diagnosed with CP, born between 1 January 
2006 and 31 December 2009 in Queensland will be invited 
to participate. These children had participated in two 
prospective longitudinal cohort studies between the ages 
of 1.5 and 5 years and will be invited to return at 8–12 
years. The inclusion criteria included children with CP 
defined as a permanent (but not unchanging) disorder 
of movement and posture that resulted from an insult to 
the developing central nervous system. The characteristic 
signs were spasticity, movement disorders, muscle weak-
ness, ataxia and rigidity.14 The exclusion criteria included 
i) children with a progressive or neurodegenerative lesion 
and ii) children born outside Queensland in the relevant 
birth years.
ethics approvals
There are no known health or safety risks associated 
with participation in any aspect of the described study. 
All radiological tests (including anterior-posterior (AP) 
pelvis, spine as required) and full body and lateral distal 
femur DXA for body composition and bone health have 
been reviewed for radiation safety. All families gave written 
informed consent to participate, and they were able to 
withdraw their child from the study at any time without 
explanation, without any penalty from staff at Children’s 
Health Queensland, or any effect on their child’s care. 
Data collected in this study have been stored in a coded 
re-identifiable form (by ID number).
ascertainment of the cohort
Prospective entry of birth years Queensland (born in 
2006, 2007, 2008, 2009) who were entered from diagnosis 
commencing at 18 months and followed until school 
age (5 years) (n=245) in the Australian CP child study 
were invited to participate in the PREDICT-CP follow-up 
study. State-wide recruitment was established in collab-
oration with the Queensland Cerebral Palsy Register 
with data collection at tertiary referral hospitals. In cases 
where the diagnosis of CP was unclear, or where there 
was a suggestion of a progressive or degenerative course, 
further investigations (such as metabolic screening) were 
requested before a diagnosis of CP was confirmed. Chil-
dren detected after 18 months of age were entered into 
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the study at the time of diagnosis, offered brain MRI at 
entry and were followed up with serial motor assessments 
and other outcomes until 5 years.
The recruited sample born in Queensland (n=245) in 
the birth years of 2006, 2007, 2008 and 2009 are repre-
sentative of a population based sample.49 The sample is 
classified according to GMFCS for 2–18 years, a five-level 
classification system of children’s functional gross motor 
severity.39 It is based on self-initiated movements, anti-
gravity postures and motor skills expected in a child aged 
5 years.50 Children who are independently ambulant are 
classified as GMFCS I or II, those requiring an assistive 
mobility device to walk classified as GMFCS III and those 
in wheeled mobility as GMFCS IV and V. The recruited 
sample included children who were functioning at 5 
years of age at GMFCS level I=96 (39.2%), II=38 (15.5%), 
III=38 (15.5%), IV=35 (14.3%) and V=38 (15.5%), of 
whom 146 were male (59.6%), of spastic motor type 
208 (84.9%) and unilateral 78 (31.8%) or bilateral 165 
(67.3%) motor distribution (figure 1). Children will be 
assessed during their 8–11 birth year at the Centre for 
Children’s Health Research in Brisbane. Comorbidities 
and need for medical management will be screened.
procedures
Children and families participated in previous research 
projects (NHMRC 569605 and NHMRC 465128) and were 
born in Queensland will be approached to participate in 
the current study. After providing informed consent, the 
child and their caregiver are invited to attend the Chil-
dren’s Health Research Centre and the Lady Cilento 
Children’s Hospital, a tertiary referral centre for 1–2 days 
visit. All recent medical, surgical and neurological visits 
that had occurred since their last visit will be screened 
(from their medical records and by parent report) to 
confirm any changes in diagnosis of CP, differential diag-
nosis by neurological assessment (by a paediatrician, child 
neurologist or paediatric rehabilitation specialist). Expe-
rienced allied health researchers performed all motor, 
upper limb, language and cognitive assessments at the 
Figure 1 Summary of surveillance and outcome measures for the PREDICT study.
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visit. Physiotherapists will check range of motion, clinical 
measures of spasticity, then rate the GMFCS classifica-
tion, gait pattern and will measure the pelvic and spine 
radiographs where indicated according to standardised 
protocols.23
classification measures
All children with CP at all levels of ability (GMFCS I–V) at 
8–12 years will be classified as mentioned below.
Functional severity
The GMFCS has internationally established validity, reli-
ability and stability for the classification and prediction of 
motor function of children with CP aged 2–12 years.50–52 
It has an acceptable inter-rater and intrarater (test–
retest) reliability (generalisability coefficients 0.93 and 
0.68, respectively).51 Two physiotherapists, trained in the 
use of the GMFCS, independently observed and classified 
children in one of five functional categories.50
Classifications of gross motor abilities change with 
age and therefore separate descriptions were used for 
different age bands. In the present study, the 6–12 years 
descriptions from the extended and revised GMFCS 
(GMFCS-ER) will be  used.53 The GMFCS has been 
correlated with a number of motor scales, as well as CP 
motor type and distribution.54
Motor type and distribution
Motor type was classified as spastic, dystonic, ataxic, 
hypotonic, choreoathetosis, mixed CP or unclassifiable 
according to Surveillance of Cerebral Palsy in Europe 
guidelines.55 Distribution was classified by number of 
limbs impaired, unilateral and bilateral distribution 
(hemiplegia, diplegia, triplegia, quadriplegia) by at least 
two independent raters. The Dyskinesia Impairment 
Scale56 will be undertaken for those participants with a 
motor-type (primary or secondary) diagnosis of dystonia 
and/or choreoathetosis. This is an important assessment 
to measure the motor capacity and function of children 
with these particular motor types.57
Functional performance
The Functional Mobility Scale58 at 5 m (home), 50 m 
(school) and 500 m (community)58 will be used to eval-
uate functional performance. This is a valid and reliable 
measure of a child’s usual walking ability at three distances 
(5 m, 50 m and 500 m), representing their home, school 
and wider community, respectively.59
Gait pattern
Gait patterns will be classified according to the classifica-
tion by Rodda and Graham,60 which demonstrated validity 
and reliability.61 Gait patterns for bilateral ambulant CP 
will be classified as either: i) true equinus, ii) jump knee, 
iii) apparent equinus or iv) crouch gait. For children 
with unilateral CP, gait patterns were classified according 
to the classification by Winters et al.48 This classification 
considered the sagittal plane joint movements: i) type I—
foot drop during swing phase (apparent equinus); ii) type 
II—persistent ankle plantarflexion (true equinus); iii) 
type III—maintained plantar flexion through gait cycle 
plus limited knee flexion-extension and iv) type IV—
similar to III, plus reduced hip flexion-extension. The 
classification by Winters et al had good inter-rater reli-
ability using written reports (weighted kappa, wκ=0.76) 
and videos (wκ=0.63).61–63
Upper limb function
Upper limb function is classified using the MACS.64 The 
MACS is an international system to classify hand function 
based on the child’s typical performance when handling 
objects in daily activities. The MACS is a five-level clas-
sification of how well children with CP use their hands 
to handle objects in day-to-day activities.64 This classifica-
tion system was developed for children aged 4–18 years, 
and has good reliability for use in children as young as 
2 years.64 The MACS has reported construct validity, and 
excellent inter-rater reliability (intraclass correlation 
coefficient=0.97 between therapists and 0.96 between 
therapists and parents) for children with CP.65 Children 
will be classified using the MACS by an occupational ther-
apist in discussion with the child’s carer.
Communication function
Communication function will be classified on three 
distinct but overlapping systems:
1. Communication Function Classification System 
classifies children’s performance in sending and 
receiving communicative messages using their 
typical communication means (considering all 
communication methods including Augmentative and 
Alternative Communication). It has been validated in 
children with CP aged 2–18 years. Reliability between 
professionals was moderate (κ=0.66), professional-
parent fair (κ=0.49) and test–retest strong (κ=0.82).66
2. Functional Communication Classification System 
classifies children’s performance only in sending 
communicative messages, and also considers their 
typical communication (including all communication 
methods including Augmentative and Alternative 
Communication). It has excellent inter-rater 
reliability between professionals (κ=0.94) and parent-
professional (κ=0.59).67
3. The Viking Speech Scale (VSS) was used to classify 
children’s speech production.68 The VSS is a four-
level classification system, which can be used to 
classify speech intelligibility for strangers and 
unfamiliar conversation partners of children with CP 
aged 4 years and above. It has strong content validity, 
and moderate-to-substantial inter-rater reliability 
between pairings of speech pathologists, healthcare 
professionals and parents (κ=0.58–0.81).68
Eating and drinking function
The Eating and Drinking Ability Classification System 
(EDACS) classifies the eating and drinking abilities of 
children with CP aged 3 years and above. Classification 
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is I–V and describes children’s safety and efficiency 
predominately focusing on food and fluid textures.69 The 
EDACS has strong inter-rater reliability between profes-
sionals (ICC=0.93), but fair reliability between parings of 
professionals and parents (ICC=0.45).69
primary outcomes
This prospective longitudinal study follow-up has two 
primary outcomes (hypothesis 1):
1. Gross motor function will be evaluated using the 
GMFM-66;
2. Brain lesion severity will be assessed using a structured 
scoring proforma (Fiori scale).
All additional measures are secondary outcome measures 
(hypotheses 2–4).
Body structure and function measures
Brain structure on MRI
The American Academy of Neurology practice param-
eter has recommended  that brain MRI should be part 
of the diagnosis of CP.70 Early MRI at 0–3 years was clas-
sified according to the nature and presumed timing of 
the lesion11 and analysed for brain lesion severity on the 
semi-quantitative scale of Fiori.8 Aetiology of CP was eval-
uated using MRI (location, nature and structure of the 
brain lesion).11 The brain lesion was classified by three 
main criteria:
1. The anatomical features of the lesion:
2. localisation by tissue (eg, cortical, white matter, deep 
grey matter, etc)
3. localisation by region (eg, lobes involved, laterality, 
etc)
4. extent of lesion (eg, generalised, hemispheric, lobar, 
etc)
5. The presumed aetiology of the lesion: i) genetic; ii) 
ischaemic; iii) infective and iv) other.
6. The presumed timing of the insult that caused the 
lesion:
7. Prenatal by trimester or by stage of brain development;
8. Perinatal;
9. Postnatal.
All MRIs were classified by a neurologist (SF) together 
with a neuroradiologist (AC) using a standardised method 
of image evaluation and classification. Following these 
evaluations, consensus was reached regarding the above 
three criteria. Based on preliminary data, it was estimated 
that >60% of children currently receiving a diagnosis of 
CP had early brain MRI as part of their clinical workup. 
All children (n=245) will be offered a repeat brain MRI 
at 8–12 years at 3 T. The majority will have their imaging 
performed and reported through the Herston Imaging 
Research Facility, on a Siemens 3.0 T MR scanner. The 
current minimum imaging protocol for patients with 
suspected CP consists of axial fast spin echo and coronal 
fast spin echo sequences and three-dimensional (3D) 
inversion prepared fast spoiled GRASS sequence. The 3D 
acquisitions will be reformatted in axial, coronal and 
sagittal planes, with additional oblique and curved refor-
matting. Age-specific protocols will be used to maximise 
the ability to detect cortical and white matter abnormali-
ties at different stages of myelination. All neuroimagings 
will be reviewed by a neurologist (SF, AG) and a neurora-
diologist (AC) familiar with the features of lesions that 
resulted in CP. This approach is consistent with a clinical 
practice guideline suggesting that all patients with the 
label of CP had high-quality MRI on at least one occa-
sion.70 MRI scans will be performed predominantly awake, 
without anaesthesia and after informed consent. Prepara-
tion for the MRI will be offered to families in the form of 
a training DVD explaining the scanner experience and 
practice in a ‘mock scanner’ (0.0 T) where required.
Brain lesion severity will be assessed using a structured 
scoring proforma8 based on the CH2 template,71 a highly 
detailed single-subject T1 template in Montreal Neuro-
logical Institute MNI space, which is the international 
standard for brain mapping (International Consortium 
of Brain Mapping). Lesions will be transcribed onto 
the proforma and the following measures  obtained: 
i) number of anatomical lobes involved, ii) number of 
slices on the template that were affected and iii) size and 
distribution of the lesion measured by a global lesion 
score and lesion subscores. The score (maximum of 40) 
is based on: i) anatomical lobes involved; ii) number of 
affected slices and iii) size and distribution of the lesion. 
The number of lobes and slices affected will be the 
average of summed right and left hemispheres. To calcu-
late total lesion score, each frontal, parietal, temporal 
and occipital lobes will be first considered in three 
sections: periventricular, middle and subcortical matter. 
Each section scored 0.5 if <50% of area is involved; or 1, 
for >50% involvement, with a maximum lobar score of 
3. Lobar scores for each hemisphere are summed, with 
a maximum hemispherical score of 12. The total lesion 
score is the sum of right and left hemispherical scores 
(maximum score of 24). A 1-point score (involved/not 
involved) wis also attributed to 16 anatomical structures 
including the corpus callosum, the cerebellum and the 
main subcortical structures. The final maximum score of 
the scale is, thus, a maximum of 40 (24+16).72 The Fiori 
scale method has strong inter-rater and intrarater reli-
ability72 and strong construct validity based on dMRI and 
functional severity in children with unilateral CP.73
At 8–12 years, structural MRI (sMRI)-guided and func-
tional MRI-guided dMRI scans suitable for connectivity 
analyses will be undertaken on the 3T scanner at Herston 
Imaging Research Facility (or The Lady Cilento Children’s 
Hospital at 3T for children requiring general anaesthesia 
≈ 5%). dMRI for white matter fibre tracking and whole 
brain connectomes will be acquired using our published 
protocol.74 The sMRI images will be acquired using an 
Magnetisation Prepared Rapid Acquistion Gradient 
Echo(MPRAGE) sequence at an isotropic resolution of 
1 mm. dMRI data will be preprocessed to reduce image 
artefacts,75 and the fibre orientation distribution was esti-
mated using constrained spherical deconvolution.76 
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Probabilistic tractography will be conducted using MRtrix 
software and connectivity matrices generated using previ-
ously described methods.74 Quantitative diffusivity indices 
Fractional Anisotrophy (FA) and Mean Diffusivity (MD) 
will be encoded within the connectome to assess reor-
ganisation.74 Network-based statistics77 will be performed 
between FA and MD connectomes to identify significant 
cortical networks associated with neural reorganisation. 
A second analysis will investigate brain maturation by 
comparing serial sMRI data acquired around 2 years 
with scans in the same children at 8–12 years to develop 
a predictive model of brain structure and functional 
outcome using spatiotemporal analysis of the longitu-
dinal imaging data.77
clinical history and examination
Clinical history will be reviewed (see online supple-
mentary Appendix 1: Queensland CP Child Physicians 
Checklist) to determine:
a. Presence or absence of comorbidities including 
vision impairment, hearing difficulties, epilepsy;
b. Feeding issues including presence or absence of 
gastrostomy tube and failure to thrive;
c. Respiratory difficulties including episodes of 
pneumonia and aspiration.
A comprehensive musculoskeletal examination will be 
performed by a physiotherapist to record data relating 
to joint range of movement, leg length difference, bony 
anomalies, motor type and lower limb muscle spasticity 
and contracture.78–83
anthropometry
Anthropometric measures will be collected as described 
in detail in our published growth, nutrition and physical 
activity protocol,26 including the following:
a. Body mass to the nearest 100 g using chair scales 
(Seca).
b. Height to the last completed millimetre with a 
stadiometer, or, length using a supine measuring 
board. Where a direct measure of height or length 
could not be obtained, height will be estimated from 
knee height or upper arm length using published 
validated techniques and formulas.84
c. Body mass index will be calculated as mass (kg) 
divided by height (m) squared.
d. Growth and growth velocity (Z-scores of measured 
or predicted height).
Weight and body mass index Z-scores will be 
calculated for age and sex according to the Centres 
for Disease Control and Prevention 2000 growth 
data.85
Gross motor function
Gross motor function will be evaluated using the 
GMFM-66 and GMFM-8886 by experienced research 
physiotherapists. The GMFM-88 assessed a child’s motor 
abilities in lying to rolling, sitting, crawling to kneeling, 
standing, walking, running and jumping. The GMFM-66 
comprised a subset of the 88 items identified (through 
Rasch analysis) as contributing to the measure of gross 
motor function in children with CP. The GMFM-66 will 
provide an overall measure of gross motor function and 
the GMFM-88 provides domain scores to explore specific 
motor skills.86
Upper limb performance
Children with unilateral CP whose manual ability is MACS 
I–III will be assessed on the school kids AHA, a Rasch 
measure of effectiveness of impaired hand in bimanual 
activities. Test–retest reliability was high (ICC 0.98) and 
there was predictive validity of future assisting hand use.87 
BoHA will be used for children with bilateral CP who were 
manual ability MACS I–IV. The BoHA test content was 
developed by researchers in Norway and Sweden through 
modification of the AHA test items and by generation of 
new items.88 Associations between BoHA measures and 
MACS levels showed strong correlation (Spearman’s rho: 
0.74). The person separation ratios (4.36 and 5.19) and 
the person reliability (0.95 and 0.96) for the subscales 
indicated that the children’s hand function could be 
separated into six and seven ability levels.88 BoHA is the 
first observation-based assessment of effective use of the 
hands in bimanual activities for children with bilateral CP.
Hand dominance will be assessed using the Edinburgh 
Handedness Inventory laterality quotient.89 The Edin-
burgh Handedness Inventory questionnaire consists of 
10 items regarding hand preference (right or left) in 
performing a number of everyday tasks requiring one 
(eg, writing, drawing, throwing and using scissors) or two 
hands (eg, using a broom or opening a box). The later-
ality quotient is calculated using the following formula: 
laterality quotient = (right hand–left hand/ (right 
hand+left hand)×100). The Edinburgh Handedness 
Inventory is included to objectively determine upper limb 
dominance. This classification system consists of a table 
that requires the participants to indicate which hand they 
use to perform a selection of everyday tasks.
Stereognosis relates to a participant’s ability to perceive 
and recognise objects by using only tactile information90 91 
and will be assessed on the impaired and unimpaired 
limbs, using the approach described by Sakzewski et al.91 
Participants will be required to identify objects placed in 
their hand, without any visual cues. A total of nine objects 
will be placed in the hand one at a time. Three familiar 
objects (teaspoon, key, peg) and six similar matched 
objects (safety pin and paperclip; pen and pencil; coin and 
button) will be used. With vision occluded, participants 
are presented with each item. If a participant is unable 
to grasp, manipulate or release an object, the occupa-
tional therapist assisted the participant and will move the 
object for them within their hand. A corresponding set 
of items will be used to allow participants to identify the 
object in order to minimise any errors due to incorrect 
naming of the object. Scores ranged on a scale from 0 to 
9, where participants scoring below 9 are considered to 
have impaired stereognosis.90 91
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Radiological measures of hip displacement and spine
Hip surveillance, including AP pelvis X-ray, is recom-
mended for all Australian children with CP to facilitate 
early detection and treatment of severe or progressive 
hip displacement.19 92 93 The migration percentage is 
widely accepted as the gold standard measure in hip 
surveillance,78 94 measuring femoral head displacement.95 
Other measures included the Acetabular Index, assessing 
acetabular dysplasia,96 the Hilgenreiner's epiphyseal 
angle (HEA)96 and the femoral neck-shaft angle.95 97 The 
HEA96 is a radiographic measure describing the prox-
imal femoral epiphysis and has been previously applied 
to assessment of coxa valga,98 99 but may offer prognostic 
information for hips at risk in CP. The HEA represents 
the acute angle between a line drawn parallel to and 
through the proximal femoral epiphysis and Hilgenrein-
er’s line.81 82 Physiotherapists will perform a clinical 
examination of spinal alignment and mobility to screen 
for evidence of a potential scoliosis or kyphosis. Where 
indicated, an AP spine radiograph (for scoliosis) or 
lateral (for kyphosis) will be performed. Spines where 
scoliosis was evident will be measured according to the 
Cobb angle.100
Body composition and bone health
Body composition measures and bone parameters will 
be acquired using a Lunar Prodigy DXA (GE Medical 
Systems, LUNAR, Madison, Wisconsin, USA). Body 
composition measures included FM (g) and FFM (g). 
Bone parameters include areal bone mineral density (g/
cm2) and bone mineral content (g) for all total body, 
bilateral proximal and lateral distal femur sites. The 
lateral distal femur is a common site of fracture,101 102 
with the technique previously described,102 and measure-
ments are reproducible in children with CP.103 104 The 
analysis involves creating three regions of interest, each 
containing different proportions of trabecular and 
cortical bone with results for each region of interest 
(ROI), therefore, treated independently.101 102 Addi-
tionally, the proximal and distal femoral sites are used 
to calculate bone mineral apparent density (g/cm3), 
derived from the projected bone area (cm2) to provide 
an approximation of volumetric BMD.105 All scans in this 
research are a ‘one-off’ occurrence, with the total radia-
tion dose for these five DXA scans being <15 μSv.106 This 
is equivalent to approximately 1–2 days natural back-
ground radiation exposure, and only equivalent to 3% of 
the dose constraint limit for children as research volun-
teers, up to the age of 18 years.106 The total estimated time 
for all DXA scans is 30 min, performed at the University 
of Queensland Children’s Nutrition Research Centre.
Fracture rate
Fractures will be diagnosed radiologically. Parents 
will report by telephone within 24 hours of fracture 
occurrence and will bring X-ray films and details of 
management to their study visit. Vertebral fracture will be 
diagnosed on lateral X-rays of the thoracic and lumbar 
spine when indicated. Children who were GMFCS III–V 
will undergo thoracic and lumbar spine (AP/lateral) at 
8–12 years if there were clinical signs of fracture and/or 
scoliosis/kyphosis. Radiographs are minimised to reduce 
the radiation exposure.
Sexual maturation
Legal guardians of participants will be provided with stan-
dardised Tanner stage puberty diagrams, and parents will 
be asked to evaluate the child’s current pubertal stage.107 
Parental pubertal assessment will be reviewed by a physi-
cian for precocious puberty. In cases of precocious 
puberty, a left hand/ wrist X-ray will be conducted to 
determine the bone age and relative skeletal maturity of 
children. The bone age will be used to determine if the 
CP condition is interfering with the proper growth and 
bone development of the child.
Pain
Children will complete the Paediatric Pain Question-
naire (PPQ) with adult help if required.108 The PPQ asks 
children to report their pain now (severity, type and loca-
tion), as well as the severity of the worst pain they had in 
the previous week. The PPQ’s visual analogue scale for 
pain rating provides a valid and stable measure of pain 
intensity in children and adolescents with chronic muscu-
loskeletal pain.109
Three-dimensional gait analysis and in vivo muscle mechanics
A full 3D gait analysis, including synchronised measure-
ment of muscle activation using electromyography (EMG) 
and calf muscle mechanics using two-dimensional (2D) 
ultrasound, will be performed for all children functioning 
at GMFCS I–III. Participants will walk unaided and bare-
foot at a self-selected speed over a level walkway (10 m 
in length) with four force platforms embedded in the 
laboratory floor in the centre of the walkway. Reflective 
markers will be attached to the trunk, pelvis and lower 
limbs according to the modified ‘Plug in Gait’ marker set, 
with additional clusters of three markers on each thigh 
and shank segment, and a marker on the fifth metatarsal 
head.110 Marker trajectories will be recorded at 100 Hz 
using an 10-camera, 3D motion capture system (Vicon 
Motion Systems, Oxford, UK) and ground reaction force 
data will be acquired at 1 kHz using four 510 mm×465 mm 
force platforms (AMTI, Watertown, Massachusetts, USA) 
arranged in series. Lower limb muscle activations of the 
rectus femoris (RF), medial hamstrings (MH), medial 
gastrocnemius (MG), lateral gastrocnemius (LG), soleus 
(SOL) and tibialis anterior (TA) is  recorded for both 
legs at 1 kHz using a wireless surface EMG system (Aurion 
ZeroWire, Milan, Italy). Raw EMG signals will be high-
pass filtered (Butterworth, zero-lag, fourth order, 30 Hz) 
to remove movement artefact, full wave rectified and 
low passed filtered (Butterworth, zero-lag, fourth order, 
6 Hz), and interpolated to 101 points per cycle. Non-neg-
ative matrix factorisation will be applied to extract 
muscle synergies,111 which represented neuromuscular 
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control during gait. Whole body 3D gait kinematics, 
joint moments at ankle, knee and hip joints and muscu-
lotendinous lengths for MG, LG, SOL, RF and MH will 
be computed across at least five trials using OpenSim112 
and normalised to length in standing. The Gait Profile 
Score113 will be calculated as an index of overall gait 
pathology. A digital output signal from the ultrasound 
system will be used to synchronise acquisition of all 3D 
marker, force plate and EMG data.
Two-dimensional B-mode ultrasound will be used to 
examine MG and SOL muscle function during walking 
by attaching a flat ultrasound transducer (LV7.5/65/64D, 
Telemed Echo Blaster 64 EXT-1T, Vilnius, Lithuania) to 
the surface of the skin above the MG muscle and recording 
muscle fascicle length and pennation angle changes, 
as described previously.114 Muscle fascicle behaviour 
during walking will be analysed using a semi-automatic 
process, which has been shown to be highly repeatable 
(coefficient of multiple correlation 0.88).115 The average 
of five complete strides will be used in the analysis for 
each participant to ensure the overall reliability of muscle 
fascicle length data.116 Freehand 3D ultrasound will be 
used to measure muscle size and structure of the lower 
leg muscles: MG, LG, SOL and TA.117 This method of 3D 
ultrasound is valid (within 1.3%) and reliable (ICC >0.99) 
for measuring gastrocnemius muscle volume and length 
in vivo.117 Calf muscle physiological cross-sectional area 
will be measured as the ratio of muscle volume muscle 
fascicle length, corrected for fascicle pennation angle.
activity limitations
The following measures of activity limitations for func-
tional capacity will be performed for ambulant children 
(GMFCS I–III) at 8–11 years (≈ n=172).
6 min walk test
This simple, submaximal test measures the distance 
walked over 6 min, providing information about endur-
ance during functional activities.118 The 6MWT has 
excellent test–retest reliability (ICC=0.98) in CP.119 
Percentile curves have been created on 1445 children 
with TD aged 7–16 years.120 The test will be performed 
according to guidelines of the American Thoracic Society 
on a 10 m course.121
Muscle power sprint test
The muscle power sprint test (MPST) provides an estimate 
of anaerobic power.122 The MPST requires participants 
to complete six 15 m runs as fast as possible with 10 s 
rest between each lap. Power output is calculated as the 
product of body mass and distance, divided by time.122 
The MPST has been validated against the Wingate Anaer-
obic cycling test,123 and has excellent test–retest reliability 
(ICC 0.98) in children with CP.122
10 m fast walk test
The 10 m fast walk test (10 mFWT) is a test of maximal 
walking speed over a distance considered the minimum 
for functional ambulation. The 10 mFWT has moderate 
test–retest reliability in children with CP (ICC 0.81).124
Lower limb functional strength
Thirty second repetition maximum (repmax) of func-
tional strength exercises (including sit-to-stand, lateral 
step-ups and half-kneel to stand) will be tested according 
to published recommendations.125 Functional strength 
tests demonstrate acceptable inter-tester reliability 
(ICC≥0.91; coefficient of variation (CV) 12.1%–22.7%) 
in children with CP.125 For each lower limb functional 
strength exercise, participants will be given verbal and 
visual instructions as well as two practice repetitions prior 
to testing. The exercises were assessed in the following 
order: sit-to-stand, lateral step-up dominant leg, lateral 
step-up non-dominant leg, half-kneel to stand dominant 
and half-kneel to stand non-dominant. Participants will 
be given verbal encouragement throughout. Participants 
will be given 180 s rests between exercises. If a participant 
does not complete an exercise while performing the prac-
tice attempts, they will be assigned a score of 0 and will 
not proceed to testing.
Habitual physical activity
Triaxial accelerometers (ActiGraph GT3X+, Pensacola, 
Florida, USA) will be used to evaluate the frequency, 
intensity and duration of physical activity.126 ActiGraph 
accelerometers have evidence of validity and interinstru-
ment reliability in children with TD compared with heart 
rate monitoring, direct observation, indirect calorimetry, 
whole-room calorimetry and doubly labelled water.126 
The ActiGraph has been validated for measurement of 
physical activity intensity in adolescents with CP using 
oxygen uptake as the criterion measure.127 128 ActiGraphs 
will be fitted during assessment and worn during waking 
hours for 7 days.126 Participants’ caregivers completed 
a 7-day physical activity monitor log to record wear and 
non-wear times (see online supplementary Appendix 2). 
Stored data will be uploaded to an excel macro to deter-
mine daily wear time, average counts per min, daily time 
spent in sedentary, light, moderate and vigorous activity. 
Counts will be classified using established cut-points for 
children with CP.128
Blood samples for growth hormone and vitamin D
Blood will be collected and tested for hormones and other 
markers required for optimal growth, bone and meta-
bolic health. Specifically, these tests are liver function, 
kidney function, full blood count, insulin-like growth 
factor-1, thyroid hormone, parathyroid hormone, vitamin 
D3, calcium, phosphate and iron studies. As described 
above, these parameters of growth, bone health and body 
composition are often altered in children with CP and 
are related to gross motor function classification, body 
composition, growth velocity and nutritional status. Blood 
tests are optional and consent will be obtained from the 
parent and assent from the child where possible. Blood 
samples will be collected by qualified phlebotomists, who 
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are familiar with collecting blood from paediatric subjects 
using their standard procedures. Where preferred, 
samples will be collected under general anaesthesia, if 
a patient undergoes an unrelated and non-emergency 
surgical procedure (eg, orthopaedic surgery, Botulinum 
toxin A injections, MRI under anaesthesia). Parents of 
participants will be advised if these results fall outside the 
relevant reference ranges in relation to age, gender and 
pubertal status. Parents will provide informed consent for 
information to be provided to their treating clinician who 
will take responsibility for ongoing care and follow-up.
Dietary intake
Dietary energy intake will be recorded using a 3-day 
weighed food record as validated29 using our published 
methods.26 Food records will be analysed using Food-
Works. Mean energy intake will be expressed as 
megajoules per day and as a percentage of age-specific 
and gender-specific recommendations.129
Vitamin D intake
A food frequency questionnaire will be completed by 
parents/caregivers to determine the habitual intake of 
vitamin D-containing foods by the participants. The ques-
tionnaire consists of a table that requires parents to tick 
a frequency box and record the brand of a simple list of 
foods.130
Sun exposure
A 7 day sun exposure diary will measure daily sun expo-
sure in the participants to measure ultraviolet radiation 
(UV) exposure for vitamin D adequacy. Each day, partic-
ipants will record the amount of time spent in the sun 
during each 1 hour interval (0, <15, 15 to <30, 30 to <45 
or 45–60 min) between 05:00 and 19:00 hours. Clothing 
cover (based on a clothing cover guide provided with the 
dairy) and use of sunscreen (frequency and application 
site) using established methodology will also recorded131 
(see online supplementary Appendix 3). It is proposed 
that the sun exposure diary is done at the same time as 
the physical activity monitor record to lessen the burden 
on the participants. Sun exposure diaries will be done 
within 2 weeks of serum vitamin D levels being collected, 
to allow for meaningful interpretation of sun exposure 
and vitamin D levels.
Oropharyngeal dysphagia
OPD (feeding and swallowing difficulties) will be eval-
uated during a digital video-recorded snack of 20 min. 
Children will be presented with three standardised 
boluses of five textures; puree, semi-solid, chewable, 
tough chewable and fluid. The following measures will be 
used to rate the mealtime:
1. The Dysphagia Disorders Survey (DDS)—part 2 
consists of a series of binary judgements on eight 
ingestion functions across the oral preparatory, oral, 
pharyngeal and gastro-oesophageal phases (maximum 
raw score of 22). The DDS has good reliability132 133 
and convergent validity.132–136
2. The Schedule for Oral Motor Assessment (SOMA) 
consists of seven oral motor challenge categories 
corresponding to four food textures and three fluid 
utensils. The SOMA has been validated on 127 young 
infants; 58 comparison children with typical oral 
skills, 56 with non-organic failure to thrive (aged 8–24 
months) and 13 children with CP and overt feeding 
difficulties (aged up to 42 months).137 It has strong 
inter-rater reliability (κ=1.0 in 68% of fluid category 
items and 58% of food category items) and test–retest 
reliability between boluses (κ=1.0 in 84% of items).137
3. Observations of 16 clinical signs suggestive of 
pharyngeal phase impairment (eg, cough, gurgly 
phonation, wet respiration) will be rated premealtime 
and postmealtime by a trained researcher, and rated 
according to each food/fluid texture from video by a 
speech pathologist.138–140
4. The Thomas-Stonell and Greenberg scale will be used 
premealtime and postmealtime to rate saliva loss.141 
This consisted of two observational ordinal scales (1–
5), based on severity and frequency of loss.
5. The Cerebral Palsy Child Feeding Questionnaire, 
used in the CP-Child Study142 gathered information 
on the child’s typical mealtime performance based on 
parent report, which supplemented the data obtained 
from the participant’s clinical feeding assessment.
6. The Feeding/Swallowing Impact Scale (FS-IS) 
addresses questions of carer QoL and how to 
incorporated into the economic evaluation. The 
FS-IS is a validated tool to measure the impact of 
caring for a child with dysphagia and concerns on 
caregiver QoL.143 It is an 18-item, parent questionnaire 
divided into three subsections: i) daily activities; 
ii) worry and iii) feeding difficulties. The tool was 
validated on the caregivers of 164 children (median 
age 14 months, mean: 32±44 months) with varying 
comorbidities including prematurity (born <37 
weeks) in 66 (40%) children, 144 (88%) were 
medically complex with conditions in more than one 
diagnostic-based category and 77 (47%) of children 
had feeding tubes.143
Communication
All children will have language assessed using the core 
language subtests of the Clinical Evaluation of Language 
Fundamentals screener (CELF-4),144 in addition to the 
Peabody Picture Vocabulary Test (PPVT). The CELF-4 is a 
criterion referenced assessment of language skills in chil-
dren aged 5–21 years, with Australian norms available. 
Children who were non-verbal only will complete the 
receptive subtests of the CELF-4 and the PPVT. Children 
unable to participate in standardised assessment (eg, due 
to significant cognitive, visual or motor limitations) will 
have language classified using the Triple C, a parent-re-
ported observational assessment. Communication 
performance will be indicated by parents on a communi-
cation questionnaire developed for this study (see online 
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supplementary Appendix 4), which includes information 
on augmentative and alternative communication system 
type, use, frequency and access.144
Speech production will be assessed using the verbal 
motor production assessment for children (VMPAC). 
The VMPAC145 is a diagnostic tool for the systematic 
assessment of neuromotor integrity of the motor speech 
system validated in 1434 children aged 3–12 years146. 
The following subtests of the VMPAC will be adminis-
tered:
1. Oromotor production in word sequences and 
sentences (six items): items consisted of three-word 
and four-word sequences and five-word sentences. 
These items are designed to evaluate the child’s ability 
to sequence oromotor movements across different 
plane within a linguistic context.
2. Oromotor production in connected speech and 
language (five items): this subtest assesses the child’s 
motor control (eg, motor precision) as it varied in the 
context of higher level language formulation.
3. Oromotor production in automatic verbal sequences 
(one item): this subtest allows evaluation of speech 
characteristics including pitch, resonance, vocal 
quality, loudness, prosody, intonation and rate during 
production of an automatic speech task (eg, counting 
to 10, saying the alphabet).
4. Oromotor production in word sequences and 
sentences (six items): items consisted of three-word 
and four-word sequences and five-word sentences. 
These items are designed to evaluate the child’s 
ability to sequence oromotor movements across 
different plane within a linguistic context. Oromotor 
production in connected speech and language (five 
items): this subtest assesses the child’s motor control 
(eg, motor precision) as it varied in the context of 
higher level language formulation.
5. Oromotor production in automatic verbal sequences 
(one item): this subtest allows evaluation of speech 
characteristics including pitch, resonance, vocal 
quality, loudness, prosody, intonation and rate during 
production of an automatic speech task (eg, counting 
to 10, saying the alphabet).
Paediatric evaluation of disability inventory computer adapted test
Performance of self-care will be evaluated using the 
parent-reported PEDI-CAT for the domains of self-care, 
mobility and social functioning using scaled scores 
(Rasch), which have good validity and reliability.147 The 
PEDI-CAT was developed on the basis of the original 
PEDI.148 Scaled scores (possible range 20–80) for each 
domain provide an indication of the child’s perfor-
mance along a continuum of item difficulty and are 
most suitable for research.147 Scaled scores give more 
precise results in the extreme ranges than normative 
standard scores.147 Scaled scores are recommended to 
track functional progress in children who are substan-
tially delayed.147
participation and environmental measures
Participation and environment measure for children and youth
The participation and environment measure for children 
and youth (PEM-CY) is a parent-reported instrument 
that examines participation and environment across 
three settings: i) home; ii) school and iii) community.149 
There are 10 items in the home section, 5 in the school 
section and 10 in the community setting. For each item, 
the parent is asked to identify how frequently (over the 
past 4 months) the child has participated (eight options: 
daily to never); how involved the child typically is while 
participating (five-point scale: very involved to minimally 
involved) and whether the parent would like to see the 
child’s participation in this type of activity change (no 
or yes, with five options for the type of change desired). 
For each setting, the parent is then asked to report on 
whether certain features of the environment make it 
easier or harder for the child to participate. The PEM-CY 
has reported moderate-to-good internal consistency (0.59 
and above) and test–retest reliability (0.58 and above) 
in a population of children (aged 5–17 years) with and 
without disabilities residing in the USA and Canada 
(n=576).149 The PEM-CY will be collected using either a 
paper or online questionnaire format to gain an under-
standing of the participation of children and adolescents 
and the impact of environmental barriers and facilitators.
Strengths and Difficulties Questionnaire
The Strengths and Difficulties Questionnaire150 151 is a 
33-item parent-rated questionnaire that is used to assess 
parents’ perceptions of prosocial and difficult behaviours 
in their child or child adjustment. Parents responded 
to 25 questions about their child’s behaviour in the last 
6 months using a three-point Likert scale (ie, ‘0’=not true 
to ‘2’=certainly true). These 25 questions are combined 
to create five subscales of: frequency of emotional symp-
toms; conduct problems; inattention/hyperactivity; peer 
problems and prosocial behaviour (eg, ‘considerate of 
other people’s feelings’). A total score for each scale 
(0–10) and overall total difficulties score (0–40) is calcu-
lated, with higher scores indicating more distress on all 
scales except prosocial behaviour. Scores of 17 or above 
for the total difficulties scale are used as a clinical cut-off 
point. Scores from the five subscales and the overall 
difficulties scale will be used as a measure of the child’s 
psychological functioning. The overall total difficulties 
score has been demonstrated to have moderate-to-high 
internal consistency (Cronbach's α=0.73–0.82) and test–
retest reliability (r=0.77–0.85).152
School attainment
The Australian Early Development Index is a population 
measure of development at school entry, assessing school 
readiness.153 The National Assessment Program—Literacy 
and Numeracy (NAPLAN) measures literacy/numeracy 
achievement and individual reports will be obtained from 
families as a measure of early school achievement.154 
Where applicable, consent will be obtained from parents 
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to the release of NAPLAN result by the Queensland 
Curriculum and Assessment Authority.
cognition
Raven’s coloured progressive matrices
The Raven’s coloured progressive matrices (RCPM) is an 
assessment of non-verbal intelligence for children aged 
5–11 years with intellectual delay or physical disability. It 
consists of 36 items (15–30 min) of increasing difficulty 
in which the child has to complete a pattern. RCPM has 
validity with CP and Australian norms.155 156 In 618 Austra-
lian children (aged 6–11 years), the RCPM had good 
internal consistency (0.76–0.88) and split-half reliability 
(0.81–0.90).156
Behaviour rating inventory of executive function
The behaviour rating inventory of executive function is a 
parent completed 86-item measure of executive function 
in their child’s everyday life, yielding two scores: i) the 
behavioural regulation index and ii) the metacognition 
index to form a global executive composite score. Both 
scores can be converted into T scores with ≥65 indicative 
of dysfunction.157 It has good convergent and divergent 
validity with Child Behaviour Checklist and the Behaviour 
Assessment System for Children,158 high internal consis-
tency, (Cronbach’s α=0.80–0.98) for parent form.158 159
attention and executive functioning
Conners three parent short form (Conners 3)
The Conners three parent short form (Conners 3)160 is 
a thorough assessment of attention deficit hyperactivity 
disorder (ADHD) and its most common comorbid prob-
lems and disorders in children and adolescents aged 6–18 
years. The Conners 3 will be completed by the partici-
pant’s parents or guardian and consisted of 110 statements 
and takes approximately 20 mins to complete. Parents or 
guardians rate each statement using a four-point scale 
ranging from ‘0, not true at all (never, seldom)’ to ‘3, very 
much true (very often, very frequently)’. The Conners 
3 measures the seven key areas of inattention, learning 
problems, aggression, family relations, hyperactivity/
impulsivity, executive functioning and peer relations. Raw 
scores are converted into T scores based on a large repre-
sentative normative sample based on the US consensus 
data. In addition, the Conners 3 calculates T scores for 
symptom scales including ADHD hyperactive/Impulsive, 
ADHD combined, oppositional defiant disorder, ADHD 
inattentive and conduct disorder. Both internal consis-
tency coefficients (α=0.83–0.94) and test–retest reliability 
(r=0.52–0.94) were good for the Conners 3 parent version 
total sample age range.160
The autism spectrum quotient-child
The autism spectrum quotient-child (AQ10-child) is a 
10-item parent-reported autism screening measure for 
children aged 4–11 years.161 It was developed from the 
Quantitative Checklist for Autism in Toddlers. Parents 
respond to the 10 items on a four-point Likert scale 
from definitely agree to definitely disagree. Items will be 
summed and the scale had a cut-off of 6. It had high 
internal consistency (Cronbach’s α=0.90), sensitivity 
(0.95) and specificity (0.89).161
Sleep Disturbance Scale for Children
Sleep disorders are up to four times more common in chil-
dren with CP compared with the general population and 
are linked to both physical (total body involvement, severe 
visual impairment) and environmental factors (single-
parent household, bed-sharing). The most commonly 
reported disorders include difficulty initiating and main-
taining sleep, sleep-wake transitions and sleep breathing 
disorders.162 The Sleep Disturbance Scale for Children is 
a 27-item parent-reported questionnaire that assesses 
sleep disturbance in children within the past 6 months.163 
Each item is responded to on a five-item Likert scale with 
higher values representing greater clinical severity. Items 
are summed to produce a total score and six subscores 
representing different facets of sleep disturbance: disor-
ders of initiating and maintaining sleep, sleep breathing 
disorders, disorders of arousal, sleep-wake transition 
disorders, disorders of excessive somnolence and sleep 
hyperhidrosis. It has good internal consistency (Cron-
bach’s α=0.71–0.79), test–retest reliability (r=0.71) and 
discriminative validity in distinguishing between clinical 
and community samples.163
QoL measures
Condition-specific QoL measures
The cerebral palsy quality of life-child assesses well-being 
across multiple domains using parent-report (aged 4–12 
years) and child self-report from 9 years.164–166 Psycho-
metrics are excellent with Cronbach’s α 0.74–0.92 
parent-proxy report and 0.80–0.90 child self-report. 
Test–retest was adequate (ICC 0.76–0.89) and moderately 
correlated with health (r=0.30–0.51).164–166
Generic QOL
The Child Health Utility-9D is a generic instrument 
for children aged 7–11 years for which there is an algo-
rithm to give a single preference-based utility index for 
health states (giving a single generic preference-based 
indicator of each individual’s health state), making the 
data amenable for economic evaluations for interven-
tions.167–170 The EuroQoL five-dimensional descriptive 
system (EQ-5D-5L) is a generic instrument designed 
to describe and value health based on five dimensions: 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression.171 The EQ-5D-5L will be completed 
by the parent/caregiver, about themselves and scored 
using the Australian algorithm.172 173 This is relevant 
(alongside the CES) to address questions such as carers 
QoL and how to incorporate it into economic evalua-
tion.
Demographic questionnaire
Parents will be required to complete questionnaires 
related to various aspects of their child's development/
progress including participation, feeding, HRQoL, sleep, 
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fracture history, pain, executive functioning in everyday 
life, clinical comorbidities including epilepsy, psycholog-
ical functioning, treatments and interventions the child 
has received since the completion of the CP-child projects 
(see online supplementary Appendix 5). The socioeco-
nomic status of Australian families will be classified into 
tertiles using scores on the Socioeconomic Indexes for 
Areas Index of Relative Disadvantage.174
parent questionnaires
Carer Experience Scale
The Carer Experience Scale (CES) will be completed 
by primary caregivers at their study visit. This validated 
measure of care-related QoL has six domains (activities, 
support, assistance, fulfilment, control and relationship 
with the care recipient) and takes approximately 3 min 
to complete.175 The CES is scored from an algorithm 
derived from preferences of the general population 
and can be used to value carer outcomes in economic 
evaluation using index values.176
The McMaster family assessment device general functioning scale
Caring for a child with a disability can have an impact 
on the health and functioning of the caregiver and 
family unit.177 The family assessment device is a 12-item 
measure of general family functioning.178 Each item is 
rated on a four-point Likert scale from strongly agree to 
strongly disagree and the items are summed to create 
the total score. It has good internal consistency (Cron-
bach’s α=0.92), construct validity and reliability.178–180
Monitoring of resource use and direct costs of treatments
To determine the relationship between motor prognosis 
and healthcare costs, resource use and direct costs of 
treatment will be monitored using the Health Resource 
Use questionnaire14 (see online supplementary 
Appendix 6). Associations between costs (dependent 
variable) and all other outcome variables (indepen-
dent variables) including those related to growth, body 
composition and HPA will be assessed, with adjust-
ment for confounders such as brain lesion severity. 
Health-related resource use data will be collected 
including therapy frequency and duration (tradi-
tional/alternate), hospital admissions, GP and medical 
specialist visits, medications (eg, Botulinum toxin A) 
and equipment (eg, orthoses). Data will be collected 
via questionnaire,14 supplemented by consented access 
to individual hospital, Medical Benefits Scheme (MBS) 
and Pharmaceutical Benefits Scheme (PBS) records. 
Standard cost sources (MBS, PBS) will be used to apply 
unit costs to resources. Statistical approaches, which 
consider the likely skewed distribution of cost data 
(such as generalised linear models, with extensions to 
allow for correlations in the data across observations 
from multiple time points from each individual as 
described below), and diagnostic-related group costs 
for admissions to hospital) will be employed. As this 
cohort is embedded in a state-wide clinical service, we 
have consistency of interventions based on best practice 
guidelines for Botulinum toxin A, bone health and hip 
surveillance generalisable across Australia. All children 
are offered best practice treatment across the state-wide 
service.
data analysis plan
A comprehensive database has been established for 
all data collection, including clinical measures, MRI 
scoring and questionnaires so that it is entered prospec-
tively at the time of each assessment. Summary reports 
are automatically generated from the database to report 
back to families and treating clinicians after each visit. 
Biostatistics methods proposed in this study include 
analysis of binary outcomes in longitudinal studies 
using weighted estimating equations (eg, presence of 
comorbidities); multilevel mixed-effects models of 
longitudinal binary outcomes (eg, GMFCS levels) and 
generalised estimating equations for ordinal data.
sample size
We assume 95% of the total sample of 245 children 
consent to the PREDICT-CP programme (we have 98% 
retention in NHMRC 465128, 569605). For Hypoth-
esis 1,1 assuming between-GMFCS group and within-child 
variability in GMFM-66 were similar to findings by 
Rosenbaum et al,181 we were able to detect significant 
between-group differences in GMFM-66 scores at 8–12 
years according to the primary predictor variable of 
initial GMFCS group (aged 2–5 years) with >80% power 
and alpha=0.05 for each pairwise comparison. For 
comparisons between MRI classification at 2 years and 
GMFM-66 at 8–12 years, then based on GMFCS and MRI 
data from NHMRC 465128 (where GMFCS I=30%, II–
V=16% each and white matter injury=43%), assuming 
that GMFM-66 at 8–12 years has a SD of 7 units within 
each GMFCS group,181 we are able to detect a difference 
between children with white-matter damage and other 
MRI pattern types of ≥4.6 GMFM-66 points in GMFCS 
I and ≥6.7 points within each GMFCS level II–V, with 
80% power, alpha=0.05. For secondary outcomes, we 
have differing power depending on sample characteris-
tics, for example, two groups, evenly distributed, we will 
detect differences of ≥0.36 SD with α=0.05, 80% power.
statistical considerations
Summary statistics will be described using either mean 
(SD) or median (25th–75th percentile) for continuous 
variables, according to distribution, or as frequency 
(percentage) for categorical variables. Cross-sectional 
associations will be assessed using linear regression for 
interval outcome data, with effect estimates presented 
as mean difference and 95% CI, using logistic regression 
for binary outcome data, with effect estimates presented 
as ORs and 95% CI, and using Poisson regression for 
count outcome data, with effect estimates presented as 
incidence rate ratios and 95% CI. Longitudinal associ-
ations will be investigated using analyses that account 
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for the multiple observations per participant. The 
particular analysis will be determined by data struc-
ture, for example, hierarchical mixed-effects models 
or generalised estimating equations. If hierarchical 
mixed-effects models are used then ‘participant’ will be 
included in the model as a random effect, to account 
for the possible non-independence of observations 
from the same participant. When building multivariable 
models, first univariable models including all potential 
variables of interest will be constructed. Variables will be 
selected for potential inclusion in multivariable models 
based on univariable significance at the p<0.2 level. 
Multivariable models will be built in a stepwise manner 
with redundant variables eliminated using Akaike’s and 
Schwarz’s Bayesian criteria. In principle, multivariable 
models will be first constructed for the whole sample, 
then after stratification by GMFCS level. Interactions 
are investigated as appropriate. 
Missing data were treated on a case-by-case basis 
depending on the observed pattern of missingness. 
For example, if data were ‘missing at random’, we will 
use multiple imputation methods, and if data are ‘not 
missing at random’, we will use pattern-mixture models. 
There was no global rule to account for multiple 
comparisons, instead adjustment for multiple compar-
isons will be made for each separate suite of analyses 
as appropriate, bearing in mind the type I and II error 
rates for each suite. Cost data will be standardised to 
current values. Cost data are typically skewed and there-
fore will be tested for normality and transformed using 
a log, gamma or another appropriate link function for 
the multivariable analysis.
Complex multivariable analyses accounting for attri-
tion, if required, will be conducted by a biostatistician. 
The precise analyses will be determined by data struc-
ture. In principle, hierarchical mixed-effects models will 
be performed for the whole population then by GMFCS 
level. First, univariable then multivariable analyses will 
be undertaken. Variables included as fixed effects in the 
final multivariate model will be selected based on univar-
iate results if p<0.2. Redundant variables are eliminated 
from multivariable models using Akaike’s and Schwarz’s 
Bayesian criteria. All models include a random intercept 
and slope (time effect) for each participant, accounting 
for the non-independence in repeated measures from 
the same participant and allowing for heterogeneity 
between participants. For Hypothesis 1,1 we will first 
undertake univariable analyses of the association between 
quantitative MRI (primary), motor capacity (primary), 
performance and potential confounding variables (eg, 
gender) at 2–5 years with motor capacity at 8 -12 years 
using a mixed-effects model with data grouped by indi-
vidual participants to account for (up to 3) repeated 
measures between 2 and 5 years. Then all variables signif-
icant at p<0.2 will be included in the prediction model, 
before being investigated for elimination. Interactions 
will be investigated as appropriate. Missing data will be 
treated on a case-by-case basis using MAR (multiple 
imputation algorithms) or NMAR (using pattern-mixture 
models). Adjustment for multiple comparisons will be 
made for each separate analyses mindful of type I and II 
error rates, as is standard practice.
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